Chemistry:Ciladopa
From HandWiki
Revision as of 18:13, 30 July 2022 by imported>LinuxGuru (add)
Short description: Chemical compound
Clinical data | |
---|---|
Routes of administration | Oral |
ATC code |
|
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
ChEMBL | |
Chemical and physical data | |
Formula | C21H26N2O4 |
Molar mass | 370.449 g·mol−1 |
3D model (JSmol) | |
|
Ciladopa (AY-27,110) is a dopamine agonist with a similar chemical structure to dopamine.[1] It was under investigation as an antiparkinsonian agent but was discontinued due to concerns of tumorogenesis in rodents.[2][3][4][5]
References
- ↑ Voith K (1985). "The comparative long-term effects of ciladopa (AY-27,110), a chemically novel dopaminergic agonist, in 6-OHDA-lesioned and intact rats". Psychopharmacology 85 (4): 405–9. doi:10.1007/BF00429654. PMID 3927334.
- ↑ "Evaluation of ciladopa hydrochloride as a potential anti-Parkinson drug". Neuropharmacology 25 (9): 973–9. September 1986. doi:10.1016/0028-3908(86)90190-5. PMID 3774130.
- ↑ "A double-blind evaluation of ciladopa in Parkinson's disease". Movement Disorders 2 (3): 211–7. 1987. doi:10.1002/mds.870020308. PMID 3332914.
- ↑ "Advanced Parkinson's disease: use of partial dopamine agonist, ciladopa". Neurology 37 (5): 863–5. May 1987. doi:10.1212/wnl.37.5.863. PMID 3574692.
- ↑ Lang AE (August 1987). "Update on dopamine agonists in Parkinson's disease: "beyond bromocriptine"". The Canadian Journal of Neurological Sciences 14 (3 Suppl): 474–82. doi:10.1017/s031716710003794x. PMID 3315148.
Original source: https://en.wikipedia.org/wiki/Ciladopa.
Read more |